# US 2022/0025379 A1 · Methods of treating schizophrenia and other neuropsychiatric disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0025379 A1
- Document ID: US20220025379A1
- Status: Published application
- Kind: A1
- Application number: 17/413,384
- Filed: 2019-12-11
- Published: 2022-01-27
- Earliest claimed: 2018-12-11
- Applicants: University of Rochester
- Inventors: Steven A. GOLDMAN; Zhengshan LIU
- Web page: https://patentgrep.com/patent/US20220025379A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C12N 2310/122: Hairpin
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods of restoring K+ uptake by glial cells in a subject. These methods involve administering, to the subject, a SMAD4 inhibitor under conditions effective to restore K+ uptake by said glial cells. The present disclosure is also directed to methods of treating or inhibiting the onset of a neuropsychiatric disorder in a subject. These methods involve administering, to a subject in need thereof, a SMAD4 inhibitor under conditions effective to treat or inhibit the onset of the neuropsychiatric disorder in the subject.

## Claims

### Claim 1

A method of restoring K+ uptake by glial cells having impaired K+ channel function, said method comprising
administering, to the glial cells having impaired K+ channel function, a SMAD4 inhibitor under conditions effective to restore K+ uptake by said glial cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the glial cells are glial progenitor cells.

### Claim 3 (depends on 2)

The method of claim 2, wherein said administering is carried out under conditions effective to restore glial progenitor cell astrocyte differentiation.

### Claim 4 (depends on 1)

The method of claim 1, wherein the glial cells are astrocytes.

### Claim 5 (depends on 1)

The method of claim 1, wherein the SMAD4 inhibitor is an inhibitory nucleic acid molecule selected from the group consisting of a SMAD4 antisense oligonucleotide, a SMAD4 shRNA, and a SMAD4 siRNA.

### Claim 6 (depends on 1)

The method of claim 1, wherein the SMAD4 inhibitor is a small molecule selected from the group consisting of 5-Fluorouracil, valproic acid, vorinostat, and PR-629.

### Claim 7 (depends on 1)

The method of claim 1, wherein the glial cells having impaired K+ channel activity are glial cells of a subject having a neuropsychiatric disorder.

### Claim 8 (depends on 8)

The method of claim 8, wherein the neuropsychiatric disorder is schizophrenia.

### Claim 9

A method of restoring K+ uptake by glial cells in a subject, said method comprising:
selecting a subject having impaired glial cell K+ uptake, and
administering, to the selected subject, a SMAD4 inhibitor under
conditions effective to restore K+ uptake by said glial cells.

### Claim 10 (depends on 9)

The method of claim 9, wherein the glial cells are glial progenitor cells.

### Claim 11 (depends on 10)

The method of claim 10, wherein said administering is carried out under conditions effective to restore glial progenitor cell astrocyte differentiation in the subject.

### Claim 12 (depends on 9)

The method of claim 9, wherein the glial cells are astrocytes.

### Claim 13 (depends on 12)

The method of claim 12, wherein said administering is carried out under conditions effective to restore astrocyte K+ homeostasis.

### Claim 14 (depends on 9)

The method of claim 9, wherein the SMAD4 inhibitor is an inhibitory nucleic acid molecule selected from the group consisting of a SMAD4 antisense oligonucleotide, a SMAD4 shRNA, and a SMAD4 siRNA.

### Claim 15 (depends on 9)

The method of claim 9, wherein the SMAD4 inhibitor is a small molecule selected from the group consisting of 5-Fluorouracil, valproic acid, vorinostat, and PR-629.

### Claim 16 (depends on 9)

The method of claim 9, wherein the SMAD4 inhibitor is packaged in a nanoparticle delivery vehicle.

### Claim 17 (depends on 15)

The method of claim 15, wherein the delivery vehicle comprises a glial cell targeting moiety.

### Claim 18 (depends on 9)

The method of claim 9, wherein the selected subject has or is at risk of having a neuropsychiatric disorder.

### Claim 19 (depends on 18)

The method of claim 18, wherein the neuropsychiatric disorder is selected from the group consisting of schizophrenia, autism spectrum disorder, and bipolar disorder.

### Claim 20 (depends on 19)

The method of claim 19, wherein the neuropsychiatric disorder is schizophrenia.

### Claim 21 (depends on 9)

The method of claim 9, wherein said administering is carried out under conditions effective to decrease neuronal excitability in said subject.

### Claim 22 (depends on 9)

The method of claim 9, wherein said administering is carried out under conditions effective to decreases seizure incidence in said subject.

### Claim 23 (depends on 9)

The method of claim 9, wherein said is carried out under conditions effective to administering improves disordered cognition in said subject.

### Claim 24 (depends on 9)

The method of claim 9, wherein said administering is carried out using intracerebral delivery, intrathecal delivery, intranasal delivery, or via direct infusion into brain ventricles.

### Claim 25 (depends on 9)

The method of claim 9, wherein the subject is human.

### Claim 26

A method of treating or inhibiting the onset of a neuropsychiatric disorder in a subject, said method comprising:
selecting a subject having or at risk of having a neuropsychiatric disorder, and
administering, to the selected subject, a SMAD4 inhibitor under conditions effective to treat or inhibit the onset of the neuropsychiatric disorder in the subject.

### Claim at position 27

-40. (canceled)
